#1Roche#2Roche This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', ‘estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected.#3Roche Q1 2023 sales Basel, 26 April 2023 Roche#4Group Thomas Schinecker Chief Executive Officer Roche#5Q1 2023 performance Outlook Roche#6Q1 2023: Strong underlying sales excluding COVID-19 decline Group sales -3% driven by expected decline in COVID-19 testing · Strong Pharma performance (+9%) driven by ongoing portfolio rejuvenation . Good Diagnostics base business growth (+4%) • COVID-19 sales decline in line with FY 2023 expectations Roche Growth supported by key products and strong launches • • • Pharma key products Vabysmo, Ocrevus, Hemlibra, Evrysdi, Tecentriq, Perjeta, Phesgo and Polivy continuing to grow strongly Key Pharma approvals: Polivy in 1L DLBCL in the US, Hemlibra in moderate hem A in the EU, Columvi (glofitamab) in 3L+ DLBCL in Canada Diagnostics: launches of new tests in oncology, navify Algorithm Suite and navify Marketplace Update on pipeline newsflow in 2023 • • Positive Phase III results for Tecentriq + Avastin in adjuvant HCC and crovalimab in PNH achieved Pharma: 14 upcoming late-stage read-outs incl. 2 NMEs (tiragolumab, SRP-9001) and important line extensions for Ocrevus, Tecentriq, Venclexta, TNKase, Alecensa and Lunsumio • Diagnostics: CCM Vertical, LightCycler Pro, Anti-HEV IgG/IgM, HBeAg Quant, and IL-6 Neonatal sepsis Growth rates at CER (Constant exchange Rates); DLBCL= diffuse large B-Cell lymphoma; NME=new molecular entity; HCC-hepatocellular carcinoma; PNH=paroxysmal nocturnal hemoglobinuria 6#7Q1 2023: Group sales decline driven by COVID-19 sales erosion Pharmaceuticals Division Diagnostics Division Roche Group 2023 2022 Change in % Excl. CHFbn CHFbn CHF CER C191 11.7 11.2 5 9 9 3.6 5.3 -31 -28 4 15.3 16.4 -7 -3 8 CER-Constant Exchange Rates; totals may include differences due to rounding; 1 Pharmaceuticals Division sales excluding Ronapreve, Diagnostics Division base business Roche 7#8Q1 2023: Portfolio diversification ongoing CHFM 16'445 +146 -3% at CER +48 -1'626 +1'262 -333 -620 15'322 Q1 2022 Dia base business Dia COVID-19 sales Pharma Ronapreve underlying sales business AHR erosion1 Fx Q1 2023 Values in reported CHFm, variances in CERm; 1AHR: Avastin, Herceptin, Rituxan/MabThera sales erosion Diversification of Roche portfolio Q1 2018 CHF 13.6bn Q1 2023 CHF 15.3bn Roche Diagnostics Other pharma Ophthalmology Neuroscience Hemophilia A Infectious diseases Oncology Immunology AHR 8#9Q1 2023: Strong underlying growth in Pharma and Diagnostics % CER +30% +20% Pharma Quarterly sales evolution 2022-2023 Diagnostics Quarterly sales evolution 2022-2023 % CER +30% +24% +20% +8% +10% +7% +9% +9% +4% +10% +10% +3% +6% +4% +9% +0% -2% +3% 0% +0% -4% +2% 0% -10% -9% -6% -10% -20% -28% -20% Q1 Q2 Q3 Q4 Q1 2022 vs. 2021 2023 vs. 2022 -Pharma Pharma excl. Ronapreve Growth rates at CER (Constant Exchange Rates) Roche -30% Q1 Q2 Q3 Q4 Q1 2022 vs. 2021 2023 vs. 2022 --Diagnostics Diagnostics Base business 9#10Portfolio rejuvenation progressing; new launches with >50% of sales Columvi (glofitamab): first NME launch in 2023* Roche CHFM % of Pharma Sales*** 7,000 ENSPRYNG 50% PHESGO 6,000 susvimo LUXTURNA voretigene neparvovec-rzyl xofluza Evrysdi. ranibizumab injection 5,000 42% risdiplama TECENTRIQ™ atezolizumab VENCLEXTA POLIVY planbedde HEMLIBRA emicizumab-kxwh GAVRETO RONAPREVE casinivinab and indevinab 4,000 VABYSMO Lunsumic 31% mosunetuzumab 3,000 22% COLUMVI guftame 2,000 ALECENSA alectinib OCREVUS ocrelizumab ROZLYTREK 1,000 COTELLIC 0 2016 | 2017 | 2018 | 2019 | 2020 2021 2022 2023 Q1 2020 Q1 2021 Q1 2022 Q1 2023 Expected NME Launches: ⚫ crovalimab ⚫ SRP-9001 Cotellic Alecensa Luxturna Xofluza Tecentriq Polivy Ocrevus Hemlibra Rozlytrek Enspryng Phesgo Evrysdi Gavreto Ronapreve Susvimo Vabysmo Lunsumio *First launch in Canada, PDUFA date in the US is July 1st; ** SRP-9001: Accelerated US-filing by partner company Sarepta; crovalimab: First filing in China;' *Venclexta sales booked by AbbVie and therefore not included 10 10#112023 performance Outlook Roche#122023: Upcoming newsflow Pharma Tiragolumab + Tecentriq in 1L PDL 1+ NSCLC Tiragolumab + Tecentriq + chemo in 1L Esophageal Glofitamab + GemOx in 2L+ DLBCL Lunsumio + Polivy in 2L+ DLBCL* Crovalimab in PNH Roche CCM Vertical LightCycler Pro Diagnostics Modular transportation system, integrated into existing cobas connection modules Flexible real-time PCR instrument with dual IVD and Research mode Anti-HEV IgM: Immunoassay aiding in diagnosis of acute HEV infection in clinic. Anti-HEV IgG: Immunoassay aiding in detection of a recent or past HEV infection Immunoassay aiding in diagnosis, monitoring and predicting treatment response for patients with hepatitis B Immunoassay with dedicated claim aiding in diagnosis of sepsis in neonates Tecentriq + Avastin in adjuvant HCC Tecentriq in adjuvant SCCHN Delandistrogene moxeparvovec (SRP-9001) in DMD Tecentriq+chemo in adjuvant TNBC × Anti-HEV IgG and Anti-HEV IgM Tecentriq neoadjuvant/adjuvant TNBC Ocrevus 6m SC in RMS/PPMS Phesgo OBI in HER2+ BC TNKase in Stroke HBeAg Quant Alecensa in adjuvant ALK+ NSCLC Susvimo in DME Venclexta + azacitidine in 1L high risk MDS Susvimo in DR IL-6 Neonatal sepsis (claim extension) Venclexta + dexamethasone in R/R MM (t11;14) Xolair in Food allergy Neuroscience Ophthalmology Oncology/Hematology Immunology DME=diabetic macular edema; DLBCL-diffuse large B-cell lymphoma; NSCLC-non-small cell lung cancer; HCC-hepatocellular carcinoma; MM-multiple myeloma; PCR-polymerase chain reaction; SC=subcutaneous; DR-diabetic retinopathy; RMS=relapsing MS; PPMS=primary progressive MS; PNH=Paroxysmal nocturnal hemoglobinuria; TNBC-triple negative breast cancer; SCCHN-squamous cell carcinoma of head and neck; DMD=Duchenne muscular dystrophy; OBI-on-body injector; BC=breast cancer; MDS-Myelodysplastic syndrome; R/R=relapsed/refractory; IVD-in vitro diagnostics; HEV=Hepatitis E Virus; *Results are event-driven, read-outs expected 2023/24 12 1#13Corporate Executive Committee Since April 2023 Pharma Division Teresa Graham Pharma CEO* Levi Garraway Head of Pharma Dev / CMO* Hans Clevers Head of PRED Aviv Regev Head of GRED Thomas Schinecker CEO Group Diagnostics Division Group Functions Matt Sause Diagnostics CEO Alan Hippe CFO/CIO Cris Wilbur Chlef People Officer Claudia Boeckstiegel General Counsel Barbara Schaedler Head of Group Comms James Sabry Head of Partnering *Co-chair late stage pipeline committee (LSPC); PRED=Pharma Research & Early Development; gRED=Genentech Research & Early Development Silke Hoernstein Head of Strategy & Sustainability Roche 13#142023 sales outlook Sales drivers¹ Pharma: Key products with strong growth and momentum from ongoing launches Diagnostics: Base business with solid growth COVID-19 sales for Diagnostics and Pharma expected to decline by roughly CHF 5bn AHR² sales expected to erode by roughly CHF 1.6bn 1 At Constant Exchange Rates (CER); 2 AHR=Avastin, Herceptin, Rituxan/MabThera Group sales growth¹ Low single digit decline Roche 14#152023 outlook Group sales growth1 Low single digit decline Core EPS growth¹ Broadly in line with sales decline Dividend outlook Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER) Roche 15#16Pharmaceuticals Division Teresa Graham CEO Roche Pharmaceuticals Roche#17Q1 2023: Pharmaceuticals Division sales All regions delivering strong growth 2023 2022 Change in % CHFM CHFM CHF CER Pharmaceuticals Division 11,699 11,159 5 9 United States 5,853 5,489 7 6 Europe 2,071 2,072 0 5 Japan 1,390 1,337 4 18 International 2,385 2,261 5 13 CER=Constant Exchange Rates Roche 17#18Q1 2023: Strong momentum for key growth drivers Vabysmo leading growth contributor after only 5 quarters Vabysmo Ocrevus Hemlibra Evrysdi Tecentriq Perjeta Phesgo Tamiflu Polivy TNKase/Activase Ronapreve Gazyva Alecensa Kadcyla Xolair Xofluza Lucentis Actemra/RoActemra MabThera Herceptin Avastin Esbriet 14% 24% 62% 15% 11% 72% >500% 96% 23% 9% >500% 24% 9% 5% 5% >500% -35% -12% -17% -17% US Europe ■Japan -24% International -69% T -300 -200 -100 0 100 200 300 400 500 Absolute values and growth rates at Constant Exchange Rates (CER) Roche 18#19Q1 2023: Oncology portfolio growing +4% YoY CER growth Phesgo (+72%) • HER2 franchise Herceptin Perjeta (+11%) +6% • Kadcyla (+5%) Tecentriq +15% • Polivy (+96%) Lunsumio (n/a) Hematology franchise Rituxan +8% Gazyva(+24%) Avastin -24% Alecensa +9% Cotellic + Cotellic (-2%) -3% Zelboraf Rozlytrek +21% Tarceva -28% Roche HER2 franchise Kadcyla (+5%) with growth ex-US in adj. BC; China NRDL listing granted Perjeta (+11%) driven by US & International Phesgo (+72%): 35% conversion in early launch countries* Tecentriq Solid growth (+15%) driven by adjuvant NSCLC and 1L HCC Hematology franchise • Venclexta**: Expanding patient share in 1L AML & 1L CLL • • Gazyva (+24%): Growth driven by 1L FL and 1L CLL Polivy (+96%): Strong 1L DLBCL uptake ex-US; FDA approval in 1L DLBCL ⚫ Lunsumio: Global 3L+FL launch ongoing; NCCN guideline inclusion as category 2A granted Alecensa Gavreto CHFbn +95% • Good growth (+9%) and 1L ALK+ NSCLC leadership in major markets • Ph III (ALINA) in adjuvant ALK+ NSCLC expected in 2023 0.0 0.5 1.0 1.5 2.0 2.5 Q1 2023 Oncology sales: CHF 4.9bn, CER growth +4%; CER-Constant Exchange Rates; * Phesgo conversion rate is based on volumes (vials) and includes all launch countries after the 2nd quarter after the launch (30 countries); ** Venclexta sales booked by 19 AbbVie and therefore not included; BC=breast cancer; NRDL-national reimbursement drug list; HCC-hepatocellular carcinoma; NSCLC=non-small cell lung cancer; AML-acute myeloid leukemia; CLL-chronic lymphocytic leukemia; FL-follicular lymphoma; DLBCL=diffuse large B cell lymphoma; ALK-anaplastic lymphoma kinase; Polivy in collaboration with Seagen#20Polivy in 1L DLBCL: FDA approval granted Comprehensive NHL development program ongoing Uptake in 1L DLBCL accelerating NHL development program progressing Roche POLIVYⓇ polatuzumab vedotin 1L DLBCL approved in >70 countries Polivy quarterly sales Indication Regimen Phl Ph II Ph III CHF Mn YoY CER growth +96% 160 120 2L+ DLBCL (SCT ineligible) Polivy + R-GemOx 2L+ DLBCL (SCT ineligible) Lunsumio + Polivy 2L+ DLBCL (SCT ineligible) Columvi + GemOx POLARGO SUNMO STARGLO +89% 80 1L DLBCL Columvi + Polivy + R-CHP +20% 40 40 1L DLBCL (elderly unfit) Lunsumio + Polivy Approved 2L+ DLBCL (SCT ineligible) Columvi + Polivy 0 Q1 20 Q1 21 Q1 22 Q1 23 US International 2L FL Europe Japan • FDA ODAC voted 11-2 in favor of clinical benefit in 1L DLBCL • • US approval granted with label for 1L DLBCL with IPI score 2-5 · • US: Included in NCCN guideline as category 1* • UK: NICE reimbursement obtained** Lunsumio+lenalidomide CELESTIMO Ph III Columvi + Polivy + R-CHP in 1L DLBCL to be initiated in 2023 Ph III (SUNMO) Lunsumio + Polivy in 2L+ DLBCL to read out in 2023/24 • Ph III (STARGLO) Columvi + GemOx in 2L+ DLBCL to read out in H2 2023 20 20 CER=constant exchange rates; NHL=Non-Hodgkin's lymphoma; DLBCL-diffuse large B-cell lymphoma; ODAC-oncologic drugs advisory committee; IPI=International prognostic index; FL-follicular lymphoma; R-GemOx=rituxan + gemcitabine + oxaliplatin; R-CH(O)P=rituxan + cyclophosphamide + doxorubicin + (vincristine) + prednisone; *NCCN guidelines for B-Cell Lymphomas (V1.2023); **NICE: Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma [ID3901]; Polivy in collaboration with Seagen#21Phesgo: Conversion rate in early launch countries climbing to 35% Phesgo reduces administration time & costs PHESGO® Phesgo with strong global launch Roche Treatment option Administration and observation schedule* 0.5 1.5 hours Π HIV PIV 2-6 h 1h 1h → 5-8 min 15 - 30 min Phesgo Administration time Ranges driven by differences in loading and maintenance dose Global Phesgo conversion rate** Total time 40% 35% 30% ~2.5-7.5 hours 20% ~20-38 min 10% 0% 90 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22| Q3'22 Q4'22 Q1'23' 85% of patients preferred Phesgo for Subcutaneous administration over the intravenous formulation of Perjeta and Herceptin Phesgo conversion rate at 35% in early launch countries, including strong uptake in the US and Germany • Pivotal Ph I results for Phesgo OBI (on body injector) to enable patient self-administration expected in H2 Source: O'Shaughnessy J, et al. ESMO 2020 (Abstract 165MO); H-Herceptin; P=Perjeta; IV=Intravenous; *Ranges driven by differences in loading and maintenance dose; **Phesgo conversion rate is based on volumes (vials) and includes all launch countries after the 2nd quarter after the launch (30 countries); Phesgo in collaboration with Halozyme 21#22Divarasib in CRC: Positive early combination data at AACR Potential for best-in-class profile Divarasib (KRAS G12Ci) in vitro proliferation assay Roche AACR American Association for Cancer Research FDA BTD Ph lb results for divarasib + cetuximab in advanced or metastatic CRC ORR results 20 Viability IC50 UM (free drug) 0.1 0.01 0.001 0.0001 0.00001- Divarasib G12C non-G12C Viability IC50 UM (free drug) 0.1 0.01 0.001 0.0001 0.00001 a Sotorasib G12C non-G12C ++H+ Viability IC 50 UM (free drug) 10 0.1 0.01 0.0011 0.0001 0.00001- Adagrasib G12C non-G12C ** Best SLD Change from Baseline (%) 0 -20- -40 -60- -80- Best Response SD PR * Confirmed GDC-6036 Dose Level (mg) 400 400 400 400 200 400 400 400 400 200 200 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 Baseline SLD (mm) 15 74 87 144 90 121 84 84 109 38 43 65 59 59 87 86 33 43 35 189 90 24 83 59 57 83 35 62 53 Days on Treatment 181 167 181 49 84 80 169 210 167 232 138 140 197 173 167 92 168 138. 183 124 174 294 Active on Treatment Prior KRAS G12Ci Y Y N Y N N N N N N Y N N N N Y N N N Y N Y N Y Y Y N Y N Y Y Y Y N Y Y N N N N N N N N N N 161 213 342 160 188 71 265 N Y Y Y Y Y N N Y N N N Indicates 24 months on treatment • • Irreversible covalent inhibitor of KRAS G12C More potent and selective in vitro than sotorasib and adagrasib • Promising Ph lb results in CRC with unconfirmed / confirmed ORR = 66% / 62% and manageable safety profile Strong responses in several other indications, including 2L+ NSCLC • Granted FDA BTD for 2L NSCLC • Confirmatory pivotal Ph III trial in 2L+ NSCLC initiated in Q4 2022 • KRAS is the most frequently mutated oncogene, • Ph II/III (BFAST) with divarasib cohort in NSCLC ongoing occurring in more than 25% of all cancers Source: Purkey et al. AACR 2022; Phase lb study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation, Desai et al., AACR annual meeting 2023; KRAS-kirsten rat sarcoma; G12C-glycine-to-cysteine substitution at codon 12; IC 50-inhibitory concentration; BTD=breaktrough therapy designation; CRC=colorectal cancer; NSCLC=non-small cell lung cancer; ORR=overall response rate; SLD-sum of lesion diameter; SD-stable disease; PR=partial response; Lumakras (sotorasib) is a registered trademark/product of Amgen; Krazati (adagrasib) is a registered trademark/product of Mirati Therapeutics 22 22#23Tecentriq: Solid growth across all regions First PD-(L)1 with pivotal SC results filed and PDUFA set for September 15th CHFM 1,100 1,000 YoY CER growth Q1 update • • Roche Ph III (IMbrave050) results in adjuvant HCC presented at AACR; RFS primary endpoint met but OS immature ⚫ Ph III (IMpassion030) in adjuvant TNBC to be discontinued Lung franchise (NSCLC, SCLC) • EU: Strong adjuvant NSCLC launch • US: Growth in SCLC and adjuvant NSCLC +15% 900 +8% +26% 800 700 +99% 600 500 400 300 • US/EU/Japan: Further growth in 1L HCC 200 100 Outlook 2023 0 ⚫ Ph III (IMvoke010) results in adjuvant SCCHN expected in H2 Q1 20 Q1 21 Q122 Q1 23 • US Europe International Japan Ph III (SKYSCRAPER-01) Tecentriq + tiragolumab in 1L NSCLC to continue to final analysis, expected in Q3 Gl franchise (HCC) CER=Constant Exchange Rates; SC=subcutaneous; NSCLC-non-small cell lung cancer; HCC-hepatocellular cancer; SCLC-small cell lung cancer; TNBC-triple-negative breast cancer; SCCHN-squamous cell carcinoma of head and neck; PDUFA-prescription drug user fee act; RFS-recurrence free survival; OS-overall survival 23#24Hemophilia A: Hemlibra the global standard of care 37% US/EU-5 patient share reached CHFM 1,200 1,000 800 +33% 600 +146% 400 200 YoY CER growth +24% • +30% 0 Q1 20 Q121 Q122 Q1 23 US Europe International Japan CER-Constant Exchange Rates Q1 update . • ~20,000 patients treated globally Roche Hemlibra continues to penetrate across all approved patient segments • EU: Label extension to moderate patients (HAVEN 6) granted . Outlook 2023 • US/EU: Further patient share gains in non-inhibitors • SPK-8011 (dirloctocogene samoparvovec) pivotal Ph III to be initiated 24#25Crovalimab: Positive Ph III results in PNH Expanding into additional diseases: Ph I in LN initiated Ph III (COMMODORE 3) results in PNH Normalization of LDH Crovalimab development program ASH 2022 Indication Ph II Ph III Mean normalized LDH (* ULN) 10 8 N Phl COMPOSER PNH Paroxysmal nocturnal hemoglobinuria COMMODORE 1 (switch) EHA 2023 COMMODORE 2 (naïve) COMMODORE 3 (China) aHUS Atypical hemolytic uremic syndrome 1.5 × ULN SCD Sickle cell disease 1 2 3 4 5 13 17 21 25 COMMUTE-a (adults) COMMUTE-p (pediatric) CROSSWALK-c (chronic) CROSSWALK-a (acute) Time (weeks) LN Lupus nephritis Roche IR virtual event June 12th ⚫ Ph Ill China (COMMODORE 3) results show that mean LDH ≤1.5 x ULN was reached by week 3 and maintained through week 25 . Ph III (COMMODORE 2/1) results show successful disease control in naïve patients, and a favorable benefit-risk profile for patients switching from other C5 inhibitors; Safety was consistent with the known safety profile of C5 inhibitors; Results to be presented at EHA 2023 . Filed in China (BTD, Priority Review) with approval expected in 2023; Global filing planned for H1 2023 Liu et al. ASH 2022; PNH-Paroxysmal nocturnal hemoglobinuria; LN-lupus nephritis; LDH-lactate dehydrogenase; ULN-upper limit of normal;; BTD=breakthrough therapy designation 25#26Immunology: Actemra COVID-19 sales declining and Esbriet LOE Xolair autoinjector approval and Ph III food allergy readout expected in 2023 Q1 updates CHFM • YoY CER growth Roche Ph III (REGENCY) Gazyva in LN fully recruited; read out expected in 2024 ⚫ Ph III (INShore) Gazyva in PNS initiated Actemra (-12%) 2,500 +9% -5% 2,000 -2% • COVID-19 related sales declining -15% • 1,500 Shift from IV to SC ongoing, SC share at ~60% Esbriet (-69%) 1,000 500 0 Q1 20 Q121 Q122 Q123 Rituxan/MabThera (RA) Actemra SC Actemra IV Xolair ■CellCept Esbriet Pulmozyme Other • Generic competition in US and EU Xolair (+5%) • Market leader in asthma biologics and strong growth in CSU Outlook 2023 . US approval of Xolair autoinjector expected • Ph III (OUTMATCH) in food allergy read out expected • Ph III (IMAGINATION) ASO factor B in IgAN to be initiated 26 CER=Constant Exchange Rates; LOE-loss of exclusivity; RA=rheumatoid arthritis; IV-intravenous; SC=subcutaneous; LN-lupus nephritis; CSU-chronic spontaneous urticaria; ASO=antisense oligonucleotide; IgAN-immunoglobulin A nephropathy; PNS=pediatric nephrotic syndrome#27Multiple Sclerosis: Ocrevus reaching 22% patient share Ph Ill results for 6M SC Ocrevus expected in 2023 YoY CER growth +14% Q1 update CHFM 1,750 +18% 1,500 +16% 1,250 +38% 1,000 750 500 250 0 Q1 20 Q121 Q1 22 Q123 US Europe International Roche • >300k patients treated globally • #1 treatment in US and EU-5, both in total share and new to brand share • Higher retention rate than other MS medicines • Ph III (GAVOTTE/MUSETTE) high-dose Ocrevus recruitment completion imminent Outlook 2023 • US/EU: Further market share gains and growth expected • ⚫ Ph III (OCARINA II) Ocrevus SC with Q6M dosing in RMS & PPMS data read out expected • First Ph II (FENopta) data for fenebrutinib in RMS expected 27 CER-Constant Exchange Rates; MS-multiple sclerosis; SC-subcutaneous; Q6M-every 6 months; RMS=relapsing MS; PPMS-primary progressive MS#28Spinal Muscular Atrophy: Evrysdi market leader in US and Japan Increasing penetration in treatment-naive patient segment CHFM 450 400 350 300 250 +189% 200 150 100 50 Q1 21 US CER=Constant Exchange Rates Q122 Europe International Japan Q1 update YoY CER growth +62% Q123 • >8,500 patients treated worldwide; retention rate in first 12 months of ~90% globally • US: Growth driven by switch and naive patient starts, including patients <2 months old • Ex-US: Continued strong growth and share gains in all major markets • ⚫ Ph II/III (SUNFISH) 4year data presented at MDA 2023 Outlook 2023 • Continued growth and market share gains • EU: Label extension (<2 months old) based on Ph II (RAINBOWFISH) expected Roche 28#29Evrysdi: 4 year data reinforce strong efficacy and safety profile Mean change from baseline in MFM32 total score** Ph II/III (SUNFISH) results in SMA Motor function score 3 N 6 12 18 24 30 36 42 48 Visit (months) Risdiplam (n)ll Placebo (n)ll 115 113 113 112 107 103 85 100 101 98 59 57 58 58 AEs per 100PY* 900 800 700 600 500 400 Ph II/III (SUNFISH) safety in SMA H 300 200 100 0 O to ≤12 AE rates I SUNFISH Part 1 SUNFISH Part 2 Roche Evrysdi. risdiplam MDA 2023 60mg 29 29 Risdiplam* (Months 0-48) Placebos (Months 0-12) >12 to ≤24 >24 to ≤36 Time on treatment (months) • Increase in motor function scores achieved in first year sustained after 4 years, compared to natural history data >36 to ≤48 • Overall AE rate decreased over 48 months, with AES and SAES reflective of underlying disease; treatment adherence at 99% and no treatment-related AEs leading to withdrawal or treatment discontinuation • Diverse study population aged 2 to 25 years incl. more advanced disease (e.g. >65% of patients with scoliosis) reflecting a real-world population underserved in clinical trials Source: Natural history cohort, Roche data on file; courtesy of Association Institut de Myology; first presented at MDA 2021. MFM32-32-item motor function measure; SMA-spinal muscular atrophy; PY-patient years; AE-adverse event; SAE-serious adverse event; *+/- 95% Confidence interval *Baseline is the last measurement prior to the first dose of risdiplam or placebo. *Data cut-off: 6 Sep 2022. §Data cut-off: 6 Sep 2019.; Number of patients with valid results = number of patients with an available total score (result) at respective time points#30Ophthalmology: Excellent Vabysmo launch continues Double-digit US market share in nAMD and mid single-digit in DME* CHFM 500 400 300 200 100 YoY CER growth >500% 0 Q122 Q2 22 Q3 22 Q4 22 Q123 IUS Europe International Japan Q1 update Vabysmo MIAMI Roche Angiogenesis 2023 ARVO 2023 • US: Strong uptake with switches primarily from aflibercept; use in naive patients further accelerating • >860k vials shipped globally in first 14 months of launch • Positive Ph III (BALATON/COMINO) results for Vabysmo in RVO presented at Angiogenesis 2023 • ⚫ Ph Ill post-hoc analyses in nAMD & DME indicating greater retinal drying for Vabysmo vs aflibercept presented at ARVO 2023 (23-27 April) Susvimo • Positive Ph III (PAGODA/PAVILLION) results for Susvimo in DME/DR presented at Angiogenesis 2023 Outlook 2023 • Vabysmo: Continued growth and market share gains in nAMD & DME nAMD=neovascular age-related macular degeneration; DME-diabetic macular edema; RVO-retinal vein occlusion; DR-diabetic retinopathy; *Based on February 2023 patient claims data; Eylea (aflibercept) is a registered trademark/product of Regeneron 30 50#31· • Vabysmo: Positive results in RVO presented at Angiogenesis 2023 Improvement in macular leakage compared to aflibercept MIAMI Macular leakage³ Roche VABYSMO Angiogenesis 2023 Faricimab 6.0 mg (n=276) Aflibercept 2.0 mg (n=277) COMINO (C/HRVO) BALATON (BRVO) Faricimab 6.0 mg (n=366) Aflibercept 2.0 mg (n=363) Adjusted Mean BCVA Change From Baseline, ETDRS Letters 5 20 Ph III (BALATON/COMINO) results in RVO BCVA¹ CST2 Week 24 16 Week 24 +16.9 letters +17.5 letters 20 Week 24 +16.9 letters +17.3 letters 1 2 16 20 24 Time, Weeks Adjusted Mean CST Change From Baseline, μm -200 -300 1 2 Time, Weeks Vabysmo achieved robust BCVA gains and reductions in CST across both studies At week 24, more patients on Vabysmo achieved absence of macular leakage vs aflibercept Results to be filed globally with regulatory authorities 16 -311.4 μm -304.4 μm 20 Week 24 -461.6 μm -448.8 μm Proportion of Patients With Absence of Macular Leakage 100% 80% 60% 33,6% 40% 20% 21.0% I 0% 100% 80% 60% 44,4% 40% 30.0% I I 20% 0% Week 24 1BCVA was measured using the ETDRS visual acuity chart at a starting distance of 4 m; 2CST is measured as ILM-BM, as graded by central reading center; ³Macular leakage was a pre-specified exploratory endpoint in BALATON/COMINO. Macular leakage area within ETDRS grid was assessed by the reading center based on FA (fluorescein angiography) images obtained at baseline and predefined follow-up intervals, Absence is defined as area of leakage within the macula of 0 mm2 per FA; (B)RVO=(branch) retinal vein occlusion; CRVO-central retinal vein occlusion; HRVO-hemiretinal vein occlusion; BCVA-best-corrected visual acuity; ETDRS-early treatment diabetic retinopathy study; CST-central subfield thickness; BM-Bruch's membrane; Eylea (aflibercept) is a registered trademark/product of Regeneron 31#322023: Key late-stage news flow* Regulatory Phase III / pivotal readouts Compound Hemlibra Polivy + R-CHP Vabysmo Tecentriq Columvi (glofitamab) Xofluza Tecentriq + Avastin Tecentriq + chemo Tecentriq Tecentriq + chemo Tiragolumab + Tecentriq Tiragolumab + Tecentriq + chemo Venclexta + dexamethasone Venclexta + azacitidine Alecensa Phesgo OBI (on body injector) Crovalimab Columvi + GemOx Lunsumio + Polivy Delandistrogene moxeparvovec (SRP-9001) Ocrevus 6m SC Indication Moderate hemophilia A 1L DLBCL RVO Subcutaneous administration 3L+ DLBCL Influenza (paediatric 1+ yrs.) Adjuvant HCC Neoadjuvant/adjuvant TNBC Adjuvant SCCHN Adjuvant TNBC 1L PDL 1+ NSCLC 1L esophageal cancer t(11;14) R/R MM 1L high risk MDS Adjuvant ALK+ NSCLC HER2+ BC PNH 2L+ DLBCL 2L+ DLBCL DMD Milestone EU approval US approval US approval/EU filing US approval/EU filing US/EU approval EU approval Ph III IMbrave050 Ph III GeparDouze/NSABP B-59 Ph III IMvoke010 Ph III IMpassion030 Ph III SKYSCRAPER-01 Ph III SKYSCRAPER-08 (China only) Ph III CANOVA Ph III VERONA Ph III ALINA Ph I (pivotal) Ph III COMMODORE 1/2 Ph III STARGLO Ph III SUNMO** Ph III EMBARK Ph III OCARINA II RMS/PPMS Stroke patients 4.5-24h Ph III TIMELESS DME Ph III PAGODA TNKase Susvimo Susvimo DR Xolair Food allergy Outcome studies are event-driven: timelines may change; i ** Results are event-driven; read-outs expected in 2023/24 Ph III PAVILION Ph III OUTMATCH Roche EU filing ༨༨ 32 32#33Diagnostics Division Matt Sause CEO Roche Diagnostics Roche#34Q1 2023: Diagnostics Division sales Good base business growth, partially offsetting COVID-19 sales decrease CER=Constant Exchange Rates 2023 2022 Change in % CHFM CHFM CHF CER Diagnostics Division 3,623 5,286 -31 -28 Core Lab 1,928 1,896 2 7 Molecular Lab 593 1,189 -50 -48 Point of Care 397 1,466 -73 -72 Diabetes Care 376 417 -10 -5 Pathology Lab 329 318 3 7 Roche 34#35Diagnostics Division sales growth by quarter Good base business growth in Q1 2023 55% 48% 31% 24% 18% 17% 9% 10% 7% 8% 4% 3% 11% 8% Diagnostics Division sales growth Base business sales growth' 0% -4% -9% -28% Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 1.2bn 1.3bn 1.0bn 1.2bn 1.9bn 1.2bn 0.6bn 0.5bn 0.3bn COVID-19 sales Growth rates and absolute values at CER (Constant exchange Rates); 1 Quarterly sales growth excluding COVID-19 sales Roche 35#36Q1 2023: Diagnostics Division highlights Good base business growth, partially offsetting COVID-19 sales decrease Roche CHFbn Core Lab Molecular Lab -48% Point of Care -72% Diabetes Care -5% YoY CER growth • +7% Immunodiagnostics (+9%) Clinical Chemistry (+9%) • Custom biotech (-9%) • Virology base business (+12%) • Blood Screening (+15%) • Cervical Cancer (+22%) • COVID-19 (-87%) . . POC Rapid A/G (-87%) POC Molecular (-27%) POC base business (+13%) Blood glucose monitoring (-4%) Insulin delivery systems (-20%) Advanced staining (+6%) • Companion diagnostics (+11%) EMEA Pathology Lab +7% North America • . Asia-Pacific Latin America 0.0 0.5 1.0 1.5 2.0 CER-Constant Exchange Rates; POC=point of care; EMEA-Europe, Middle East and Africa; 36 56#37Q1 2023: Diagnostics Division regional sales Strong base business growth across all regions impacted by lower COVID-19 sales Roche North America -39% ~28% of divisional sales EMEA -30% ~35% of divisional sales Latin America -8% ~7% of divisional sales Asia Pacific -15% ~30% of divisional sales Growth rates at CER (Constant exchange Rates); EMEA-Europe, Middle East and Africa 37#38Largest installed base worldwide with significant growth potential 2022 Growth cobas infinity lab +3% Lab SW Solutions HE600 BenchMark ULTRA/ ULTRAPLUS DP200/DP600 +12% Growth rates from 31.12.2021 to 31.12.2022 (Total installed modules as of 31.12.2022) +10% +4% cobas 4000/6000/80001 Roche +122% cobas pro/pure +9% Preanalytics / Connectivity +30% Ⓡ cobas 5800/6800/8800 +7% LightCycler / MagnaPure +29% +24% cobasⓇ Liat 1 cobas 6000 has been discontinued in CE mark countries and replaced with cobas pro/pure systems 38 58#39Core Lab menu expansion driving future growth >240 assays running on >100k installed cobasⓇ serum work area instruments Anti-p53 (CE) Launches in 2021, 2022 and upcoming4 Anti-HEV IgG and Anti-HEV IgM (CE) GAAD² (CE) Fentanyl³ (CE, US) sTfR Gen 22 (CE) CRP4 (CN) Maxi-Multipack RBSS (CE) HBeAg Quant (CE) Interferon Gamma (CE) NT-proBNP diagnosis ICON-RL² (US) EBV EBNA IgG (CE) EBV VCA IgG (CE) EBV IgM (CE) GAAD (CE) NT-proBNP claim extension 1 (CE) TnT-hs claim extension1 (CE) PCT CE claim extension1 (CE) Vit D total III2 (CE & US) Anti-HBe (US) Sirolimus (CN) HBsAg Confirmatory² (CE) Alzh CSF biomarkers (CE) Immuno chemistry assays IGRA SARS-CoV-2 (CE) HCV Duo (CE) Anti-HAV 112 (CN) HBsAg Confirmatory² (US) AFP-L3 (CE) FT4 IV² (CE) Alzh CSF biomarker (US) NT-proBNP STRONG-HF (GL) Cortisol III urine application² (CE) tTAU CSF (Ver 2) Elecsys progesterone Diluent² FT4 IV² (US) IL6 - Claim extension neonatal (CE) Vitamin D total III2 (CN) Clinical chemistry assays Benz 22 (US) NH3L2 (CN) Roche ASTP2/ALTP2 cobas 3032 (CE/US) ASTP2/ALTP2 cobas C 5032 (CE/US) BENZ2² (US) sTfR Gen.22 (CN)2 free PHNY2 Launched in 2021 Launched in 2022 Upcoming Launches 1 Claim extension, 2 Product update; 3 Partner Channel. EBV: Epstein-Barr-Virus; 4 non exhaustive, EBNA: Epstein-Barr virus nuclear antigen, VCA: viral capsid antigens, IgM: Immunoglobulin M, anti-p53: autoantibodies, GAAD: in-vitro diagnostic multivariate index assay, NT-proBNP: N-terminal prohormone of brain natriuretic peptide, TnT-hs: Troponin T-high sensitive, PCT: Procalcitonine, Vit D: vitamin D, Anti-HBe: hepatitis B e antigen (HBeAg), HBsAg: hepatitis B surface antigen, Alzh CSF: Alzheimer's disease Cerebrospinal Fluid, SARS-CoV-2: severe acute respiratory syndrome coronavirus 2, HCV: Hepatitis C virus, Anti-HAV: antibodies against Hepatitis A virus, AFP-L3: Lectin-reactive fraction of alpha-fetoprotein, FT4: Free Thyroxine (T4), HEV: Hepatitis E virus, 39 RBSS: Roche Blood Safety Solution, NT-proBNP STRONG-HF Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP testing of Heart Failure Therapies, tTau CSF: total tau protein concentration in human cerebrospinal fluid (CSF), IL6: Interleukin-6, sTfR Gen 2: Soluble Transferrin Receptor Generation 2, CRP4: C-reactive protein generation 4, BENZ: Benzodiazepines, NH3L2: Ammonia Gen.2, ASTP2: aspartate aminotransferase with pyridoxal phosphate activation Gen.2, ALTP2: alanine aminotransferase with pyridoxal phosphate Gen.2, free PHNY2: free phenytoin.#40navify Marketplace and Algorithm Suite Roll-out of two new digital solutions which will drive operational and clinical excellence Roche Customer base Laboratories Roche and 3rd party customers 1 Middle ware, » Customer access to Portal/Marketplace² Roche instruments NEW Access to applications³ navify Algorithm Suite navify Inventory 3rd party devices cobas infinity Central Lab navify Monitoring navify Control IT systems1 navify Portal/ Marketplace navify Portal/ NEW Marketplace digital store to directly connect to our and 3rd party's portfolio of innovative and certified applications 2 navify Portal for customers; navify Marketplace for non-customers, 3 Embedded in Network or with user-interface navify Analytics NEW navify Sample Tracking navify Algorithm Suite partnership with laboratories to provide trusted clinical diagnosis & decision support for clinicians 40 40#41VENTANA FOLR1 (FOLR1-2.1) RxDx assay First FDA approved FOLR1 companion diagnostic test for ovarian cancer Roche First Line Treatment Testing chemo or chemo + bevacizumab Progression for 80% of patients • VENTANA FOLR1 (FOLR1-2.1) RxDx Assay 35% of patients³ FOLR1 positive mirvetuximab soravtansine-gyxn Second Line Treatment (ELAHERE®) 322k estimated cases of ovarian cancer worldwide (2021)1 First FDA-approved IHC companion diagnostic test for determining FRa protein expression in epithelial ovarian cancer (EOC) Enables pathologists to identify patients who may be eligible for a new therapy, ELAHERE Ⓡ 2 • Runs on automated BenchMark series of instruments 1 Clarivate Epidemiology Report: Ovarian Cancer, Clarivate Plc. Accessed 04/07/2023; 2 Results from the SORAYA clinical study demonstrated -32% of eligible patients showed a partial or complete response to ELAHERE therapy; 3 The VENTANA FOLR1 (FOLR-2.1) RxDx Assay was used as part of the SORAYA clinical study to identify patients whose tumors were positive for FRa protein (≥ 75% of viable tumor cells with moderate (2+) and/or strong (3+) membrane staining). In this study, approximately 35% of ovarian cancer patients expressed high levels of FRa (defined as ≥ 75% tumour cells staining with 2+/3+ intensity) and were considered FRα-positive by the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. Roche. VENTANA FOLR1 (FOLR-2.1) RxDx Assay. US Package Insert. 2022. Matulonis UA, et al. Abstract LB4. Presented at Society of Gynecologic Oncology 2022 Annual Meeting on Women's Cancer. March 18-21, 2022. 41#42Diagnostics key launches 2023 Roche Area Product CCM Vertical Description Modular transportation system, integrated into the existing cobas connection modules, allowing for overhead sample transportation over different work areas or different floors enabling effective use of lab space Markets Status Global Core Lab cobas pro integrated solutions Scalable and modular serum work area analyzer for mid to high volume clinical chemistry and immunochemistry testing China Instruments Automation cobas pure integrated solutions Serum work area analyzer for low to mid volume clinical chemistry and immunochemistry testing on a footprint of two square meters China Molecular Lab LightCycler Pro Point of Care cobas pulse Pathology Lab IDH1 R132H (IDH Glioma) Flexible real-time PCR instrument with dual IVD and research mode as well as enhanced system features Handheld device combining professional glucose meter and a digital platform to host digital clinical decision support applications (from Roche and third parties) Neuropathology Immunohistochemistry (IHC) solution supporting the detection of tumor cells with the IDH1 R132H mutation aiding pathologists to render a diagnosis of gliomas Anti-HEV IgM: Immunoassay aiding in the diagnosis of acute HEV infection in clinical settings; Anti-HEV Anti-HEV IgG and Anti-HEV IgG: Immunoassay aiding in the detection of a recent or past HEV infection and enabling accurate IgM seroprevalence determinations. The two assays expand the hepatitis panel (HAV, HBV, HCV, HEV) on the same analytical platform US & CE US US CE Tests Core Lab HBeAg Quant Immunoassay aiding in diagnosis, monitoring and predicting treatment response for patients with hepatitis B viral infection CE IL-6 Neonatal sepsis (claim Only immunoassay available on the market with dedicated claim and supporting evidence aiding in extension) diagnosis of sepsis in neonates, with potential to reduce newborn mortality RUO Amyloid Plasma Assays (pTau181 & ApoE4) RUO Digital Pathology Algorithm: PD-L1 SP142 navify Algorithm Suite Menu for navify Algorithm Suite Pathology Lab Digital Solutions Lab Insights cobas infinity lab 3.05 navify Marketplace navify Sample Tracking CE Two qualitative immunoassays measuring the phosphorylated Tau 181 protein and apolipoprotein E4 in human plasma for research use only US Digital pathology algorithm aiding pathologists in scoring PD-L1 (SP142) breast samples, ensuring a standardized approach and an adjunctive tool to augment diagnostic confidence for research use only Digital solution providing access to an open library of certified IVD-based clinical algorithms Certified clinical algorithms for oncology applications such as colon and liver cancers Next-generation lab middleware enabling ecosystem of cloud-based solutions for quality control and instrument maintenance Global Selected markets1 Selected markets1 Global Digital marketplace offering lab customers full range of innovative applications (from Roche and third parties) Selected markets¹ Open digital solution offering sample tracking beyond the lab setting (from IVD-sample creation to lab Selected markets1 reception) to improve testing traceability and quality 1 Selected markets: 14 countries with first releases // CE: European conformity; RUO: Research use only; PCR: Polymerase chain reaction; IVD: In vitro diagnostic; IDH: Isocitrate dehydrogenase; HEV: Hepatitis E virus; HAV: Hepatitis A virus; HBV: Hepatitis B virus; HCV: Hepatitis C virus 42 42#43Finance Alan Hippe Chief Financial Officer Roche#44Q1 2023: Highlights Sales Group sales decline of -3% resulting from erosion of COVID-19 related sales Solid Pharma and Diagnostics underlying business growth Currency impact on sales • Negative currency impact of -4%p primarily by the JPY, EUR and CNY Growth rates at CER (Constant exchange Rates) Roche 44#45Q1 2023: Regional Pharma and Group sales bridge +6% +5% +13% +18% -28% -3% -7% Pharma Division +9% +366 +224 +101 +286 -1,480 -503 -1,123 -620 United States Europe Intl. Chugai Dia Division Group Fx1 Group (Japan) CHF Absolute values in CHFm at Constant Exchange Rates (avg full year 2022); 1 avg. full year 2022 to avg Q1 2023 fx impact Roche 45 445#46Exchange rate impact on sales growth Negative impact driven by the JPY, EUR and CNY CER sales growth Q1 2023 VS. Q1 2022 -3.1% -0.7p +0.1p -0.9p -0.4p -1.2p -0.2p -0.4p -6.8% CER EUR APAC USD LATAM JPY Other Other Europe CHF CER = Constant Exchange Rates (avg full year 2022) Roche CHF sales growth Q1 2023 VS. Q1 2022 46 46#47Expected 2023 currency impact CHF / USD Assumed avg. YTD 2023 0% -3% -4% -4% 0.95 0.95 0.94 0.92 0.93 0.92 0.92 0.92 Roche Assuming the 31 March 2023 exchange rates remain stable until end of 2023, 2023 impact¹ is expected to be (%p): Q1 HY Sep FY 0.92 0.92 0.93 0.91 0.91 0.91 0.91 0.91 0.91 0.91 0.91 0.91 YTD Monthly avg fx rates 2023 Fx rates 31 Mar 23 Average YTD 2023 - Average YTD 2022 Sales -4 -5 -5 -4 CHF / EUR Assumed avg. YTD 2023 Core operating -5 -4 -4% -4% -2% -1% profit 1.04 1.03 1.01 Core EPS -6 -5 1.00 0.99 0.99 0.99 0.99 1.00 0.99 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 Monthly avg fx rates 2023 Fx rates 31 Mar 2023 Average YTD 2023 Average YTD 2022 1 On group growth rates 47#48Empty#49Upcoming virtual ESG IR event on environmental sustainability Roche Roche ESG Event on May 23 Environmental Sustainability 15:30 - 17:00 CEST / 14:30 - 16:00 BST 09:30 11:00 am EDT / 6:30 - 8:00 am PDT Why does ESG matter? Alan Hippe, Chief Financial Officer Environmental sustainability through operational and product innovation Carbon emissions and the future of energy Scott Hemphill, Global Expert in Environmental Sustainability Sustainable construction Georg Singewald, Head of Global Manufacturing Science, Technology and Engineering Product stewardship in Pharma and Diagnostics Ursina Kohler, Head of Product Stewardship Water and waste management, and site remediation efforts Richard Huerzeler, Chief Environment and Remediation Officer Environmental sustainability in our supply chain Marielle Beyer, Head of Global Procurement 49 49#50Doing now what patients need next#51Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (PRED) Genentech research and early development (gRED) Spark Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information Roche#52Changes to the development pipeline Q1 2023 update New to phase III RG6149 astegolimab (Anti-ST2) - COPD New to phase I New to phase II 1AI: 2 NMES: 1 NME: RG6107 crovalimab - lupus nephritis RG6501 OpRegen - geographic atrophy RG6341 NME- chronic cough 1 Al: 1 Al: RG6237 latent myostatin - FSHD RG7159 Gazyva - pediatric nephrotic syndrome Removed from phase I Removed from phase II Removed from phase III 3 NMES: 1 NME: 2 Als: RG6129 HLA-A2-MAGE-A4 x CD3 - solid tumors RG6354 zinpentraxin alfa (PRM-151) - myelofibrosis RG6290 MAGE-A4 ImmTAC - solid tumors RG6312 NME - geographic atrophy Status as of April 26, 2023 Roche New to registration Approvals RG7446 Tecentriq + cabozantinib - RCC adv RG7446 Tecentriq + paclitaxel - TNBC adj 1 AI (US): RG7596 Polivy - 11 DLBCL NME approval in other territory than US and EU: RG6026 Columvi (glofitamab) - 3L+ DLBCL (First approved in Canada) I I 52 52#53Roche Group development pipeline Phase I (50 NMES + 12 Als) Roche RG6007 HLA-A2-WT1 x CD3 AML Columvi (glofitamab) RG6026 monotherapy + combos RG6058 tiragolumab combos RG6076 englumafusp alfa (CD19-4-1BBL) heme tumors heme & solid tumors combos RG7802 RG7827 RG7828 CHU cibisatamab + T solid tumors RG6026 FAP-4-1BBL monotherapy + combos Lunsumio monotheraphy + combos glypican-3 x CD3 solid tumors tiragolumab + T heme tumors tiragolumab +T+ chemo RG6058 solid tumors tiragolumab + T heme tumors CHU codrituzumab HCC tiragolumab +T RG6114 RG6156 inavolisib (mPI3K alpha inh) EGFRvIII x CD3 solid tumors CHU CD137 switch antibody solid tumors glioblastoma CHU RAS inhibitor solid tumors RG6107 RG6139 crovalimab RG6160 cevostamab (FcRH5 x CD3) r/r multiple myeloma CHU SPYK04 solid tumors RG6180 RG6171 giredestrant (SERD) solid tumors SQZ PBMC vaccine solid tumors RG6180 autogene cevumeran + T solid tumors RG6107 crovalimab lupus nephritis RG6185 belvarafenib (pan-RAF inh) + Cotellic + T solid tumors RG6287 aGVHD RG6357 RG6358 RG62994 tobemstomig (PD1 x LAG3) autogene cevumeran + pembrolizumab dirloctogene samoparvovec (SPK-8011) SPK-8016 ASO factor B Phase II (23 NMES + 9 Als) Columvi (glofitamab) + chemo 1L ctDNA high risk DLBCL NSCLC NSCLC neoadj-adj cervical cancer 1L PD-L1+mSCCHN sickle cell disease solid tumors 1L melanoma hemophilia A hemophilia A with inhibitors to factor VIII RG6189 FAP-CD40 ± T solid tumors RG6315 immunologic disorders RG6341 RG6194 runimotamab (HER2 x CD3) BC RG6421 TMEM16A potentiator RG6234 forimtamig (GPRC5D x CD3) multiple myeloma RG65363 vixarelimab cystic fibrosis immunology RG7854/ ruzotolimod (TLR7 ago [3])/ RG6346/ RG6264 Phesgo OBI RG6279 eciskafusp alfa (PD1-IL2v) + T RG6286 HER2+ BC solid tumors colorectal cancer RG7828 Lunsumio SLE CHU anti-HLA-DQ2.5 x gluten peptides celiac disease RG6084** RG6359 RG1662 xalnesiran (siRNA)/ PDL1 LNA SPK-3006 basmisanil Dup15q syndrome CHU RAY121 immunology RG6042 tominersen RG6292 CD25 MAb combos heme & solid tumors RG6006 zosurabalpin (Abx MCP) RG6323 IL15/IL15Ra-Fc + T solid tumors RG6319 LepB inhibitor complicated RG6330 divarasib (KRAS G12C) solid tumors RG6035 BS-CD20 MAb RG6333 CD19 x CD28 + Columvi (glofitamab) r/r NHL RG6091 rugonersen (UBE3A LNA) RG6344 BRAF inhibitor (3) solid tumors RG6163 RG6392 RG6411 RG6433 SHP2i combos oncology solid tumors solid tumors RG6440 Anti-latent TGF-ẞ1 (SOF10) solid tumors RG6512 FIXa x FX hemophilia RG6182 RG6289 RG6418* RG7637 RG6120 MAGLI selnoflast bacterial infections urinary tract infection multiple sclerosis Angelman syndrome psychiatric disorders multiple sclerosis Alzheimer's inflammation RG6100 semorinemab RG6102 trontinemab latent myostatin + Evrysdi IgA nephropathy chronic cough HBV Pompe disease Huntington's Alzheimer's Alzheimer's SMA RG6237 latent myostatin FSHD RG6416 bepranemab Alzheimer's RG7314 balovaptan RG7412 crenezumab post-traumatic stress disorder familial Alzheimer's healthy pts RG7816 alogabat (GABA Aa5 PAM) zifibancimig (VEGF-Ang2 DutaFab) RG6524 DLL3 x CD3 x CD137 RG65261 RG65382 camonsertib P-BCMA-ALLO1 solid tumors solid tumors multiple myeloma RG6209 RG6351 RG7921 CHU psychiatric disorders nAMD retinal disease retinal disease RVO RG7906 ralmitaront RG7935 RG6179 prasinezumab anti-IL-6 ASD schizophrenia Parkinson's DME RG62994 ASO factor B RG6501 OpRegen RG7446 RG7601 Morpheus platform Venclexta + azacitidine solid tumors r/r MDS Status as of April 26, 2023 anti-IL-8 recycling antibody RG-No-Roche/Genentech; CHU - Chugai managed; SQZ - SQZ Biotechnology managed; 1Repare Therapeutics managed; 2Poseida Therapeutics managed; ³Kiniksa Pharmaceuticals managed; 4IONIS managed; T-Tecentriq; BS-Brain Shuttle; OBI-On-Body Delivery System; *also developed in Immunology; **combination platform Additional Indication (AI) Oncology/Hematology Immunology Infectious Diseases endometriosis RG7774 vicasinabin (CB2 receptor agonist) New Molecular Entity (NME) geographic atrophy geographic atrophy DR Metabolism Neuroscience Ophthalmology 53 Other#54Roche Group development pipeline Phase III (9 NMES + 40 Als) RG3502 RG6026 Kadcyla + T HER-2+ eBC high-risk RG3648 Xolair Columvi (glofitamab) + chemo tiragolumab + T tiragolumab + T RG6058 tiragolumab +T tiragolumab + T tiragolumab + T 2L+ DLBCL 1L PD-L1+ NSCLC 1L esophageal cancer locally advanced esophageal cancer stage III unresectable 1L NSCLC 1L non-squamous NSCLC RG6149 astegolimab (Anti-ST2) Gazyva Gazyva RG7159 Gazyva Gazyva Xofluza RG6152 crovalimab* RG6107 crovalimab PNH aHUS Xofluza Ocrevus higher dose RG1594 RG6114 inavolisib (mPI3K alpha inh) 1L HR+ MBC Ocrevus SC giredestrant (SERD) 1L ER+/HER2-mBC RG3625 TNKase RMS & PPMS RMS & PPMS stroke lupus nephritis membranous nephropathy systemic lupus erythematosus pediatric nephrotic syndrome influenza, pediatric (0-1 year) influenza direct transmission 1Filed in EU 2Approved in US, filed in EU Registration US & EU (1 NME + 3 Als) food allergy COPD RG6026 RG7446 Columvi (glofitamab) Tecentriq SC RG6413+ Ronapreve¹ RG6412 RG7916 Evrysdi² Roche 3L+ DLBCL all approved indications SARS-COV-2 hospitalized SMA pediatric <2months RG6171 giredestrant (SERD) RG6330 giredestrant (SERD) + Phesgo divarasib (KRAS G12C) Tecentriq + platinum chemo Tecentriq T± chemo ER+ BC adj 1L ER+/HER2+ BC 2L NSCLC Enspryng myasthenia gravis RG6168 Enspryng MOG-AD Enspryng autoimmune encephalitis T=Tecentriq PDS-Port Delivery System with ranibizumab *First filed in China in Q3 2022 NSCLC periadj NMIBC, high-risk RG6356 delandistrogene moxeparvovec (SRP-9001) DMD fenebrutinib RMS RG7845 SCCHN adj fenebrutinib PPMS RG6179 anti-IL-6 UME RG7446 T + capecitabine or carbo/gem T + Avastin 1L TNBC HCC adj Susvimo (PDS) DME RG6321 Susvimo (PDS) DR Tecentriq ctDNA+ high-risk MIBC Susvimo (PDS) WAMD, 36-week T+lurbinectedin Venclexta RG7601 RG7828 RG7853 Lunsumio + Alecensa Venclexta + azacitidine Lunsumio + lenalidomide Polivy 1L maintenance SCLC r/r MM t(11:14) 1L MDS 2L+ FL RG7716 Vabysmo (faricimab) Vabysmo (faricimab) BRVO CRVO 2L+ DLBCL ALK+ NSCLC adj New Molecular Entity (NME) Additional Indication (Al) Oncology/Hematology Immunology Infectious Diseases Metabolism Neuroscience Ophthalmology Other Status as of April 26, 2023 54#55NME submissions and their additional indications Projects in phase II and III Columvi (glofitamab)+ RG6026 RG6058 chemo 1L ctDNA+ high risk DLBCL tiragolumab + T 1L PD-L1+ cervical RG6330 divarasib (KRAS G12 C) 2L NSCLC RG7314 Roche balovaptan post-traumatic stress disorder astegolimab RG6149 (anti-ST2) New Molecular Entity (NME) Additional Indication (Al) Oncology/Hematology Immunology Infectious Diseases Metabolism Neuroscience Ophthalmology cancer COPD RG7816 alogabat (GABA Aa5 PAM) ASD tiragolumab +T RG6058 locally adv esophageal RG62991 Other ASO factor B IgA nephropathy RG7845 fenebrutinib RMS cancer RG6058 tiragolumab + T 1L non-sq NSCLC RG6341 NME chronic cough RG7845 fenebrutinib PPMS ✓ Indicates submission to health authorities has occurred Unless stated otherwise submissions are planned to occur in US and EU RG7854/ tiragolumab +T PDS-Port Delivery System with ranibizumab RG6058 1L PD-L1+ MSCCHN *First filed in China RG6346/ RG6084 ruzotolimod (TLR7 ago [3])/ xalnesiran (siRNA)/ PDL1 LNA HBV RG7906 ralmitaront schizophrenia 1IONIS managed tiragolumab+T+/- RG6058 chemo RG1662 NSCLC neoadj/adj basmisanil Dup 15q syndrome RG7935 prasinezumab Parkinson's RG6107 crovalimab sickle cell disease tominersen RG6042 RG6179 Huntington's anti-IL-6 UME tiragolumab + T tobemstomig RG6058 1L PD-L1+ NSCLC RG6139 (PD1xLAG3) RG6100 semorinemab Alzheimer's anti-IL-6 RG6179 DME solid tumors tiragolumab +T RG6058 1L esophageal cancer (CN) RG6026 Columvi (glofitamab) + chemo 2L DLBCL giredestrant trontinemab RG6171 (SERD) RG6102 RG62991 Alzheimer's 1L ER+/HER2- MBC RG6107 crovalimab* PNH (EU, US) RG6058 tiragolumab + T Stage III unresectable giredestrant latent myostatin + RG6171 (SERD) RG6237 1L NSCLC ER+ BC adj Evrysdi SMA RG6321 ASO factor B geographic atrophy Susvimo (PDS) WAMD, 36-week refill Susvimo inavolisib RG6321 (PDS) DME (US) RG6114 (mPI3K alpha inh) 1L HR+ BC RG6107 crovalimab aHUS giredestrant (SERD) + RG6171 Phesgo RG6237 latent myostatin FSHD OpRegen RG6501 1L ER+/HER2+ BC geographic atrophy RG6321 Susvimo (PDS) DR (US) delandistrogene RG6356 moxeparvovec RG6321 (SRP-9001) DMD (EU) Susvimo (PDS) WAMD, DME, DR (EU) RG6180 autogene cevumeran 1L melanoma RG6416 bepranemab Alzheimer's 2023 2024 2025 2026 and beyond vicasinabin RG7774 (CB2 receptor agonist) DR Status as of April 26, 2023 55#56Al submissions for existing products Projects in phase II and III New Molecular Entity (NME) Additional Indication (Al) Oncology/Hematology Immunology Infectious Diseases Roche Metabolism Neuroscience Ophthalmology Other RG7446 Tecentriq + Avastin HCC adj RG3502 RG7601 Venclexta r/r MM t(11:14) Phesgo OBI RG6264 RG7446 HER2+ BC RG7853 Alecensa ALK+ NSCLC adj RG7446 Tecentriq¹ NSCLC periadj RG7446 Lunsumio (mosun) + RG1594 Ocrevus SC RMS & PPMS Tecentriq RG7446 RG7159 SCCHN adj Gazyva lupus nephritis RG7828 Tecentriq + capecitabine TNKase RG3625 RG7446 or carbo/gem RG6168 stroke Enspryng myasthenia gravis RG7828 TNBC RG3648 Xolair food allergy Tecentriq RG7446 RG6152 ctDNA+ high-risk MIBC Xofluza direct transmission RG1594 lenalidomide 2L FL Lunsumio (mosun) + Polivy 2L+ DLBCL (US) Ocrevus higher dose RMS & PPMS RG7159 RG7159 Kadcyla + Tecentriq HER-2+ eBC high-risk Tecentriq High-risk NMIBC Tecentriq+ lurbinectedin 1l maintenance SCLC Gazyva Gazyva systemic lupus erythematosus Gazyva membranous nephropathy RG7159 pediatric nephrotic syndrome Vabysmo Xofluza RG7716 (faricimab) RG7601 Venclexta + azacitidine 1L MDS Enspryng Enspryng RG6152 BRVO/CRVO influenza, pediatric (0-1 year) RG6168 RG6168 autoimmune encephalitis MOG-AD 2023 2024 2025 Status as of April 26, 2023 Indicates submission to health authorities has occurred Unless stated otherwise submissions are planned to occur in US and EU OBI-On-Body Delivery System, Mosun-mosunetuzumab 1filing timeline based on data from interim analysis 2026 and beyond 56#57Major pending approvals 2023 Roche Japan-Chugai Phesgo HER-2+ BC/CC Filed Sept 2022 Actemra Cytokine release syndrome (CRS) Filed March 2023 RG7446 RG6026 US Tecentriq SC Filed Nov 2022 3L+ DLBCL EU China Evrysdi Evrysdi all approved indications RG7916 SMA presymptomatic pediatric <2mo RG7916 SMA presymptomatic pediatric <2mo RG6264 Filed Nov 2021 Filed June 2022 Columvi (glofitamab) RG6413+ RG6412 Filed Dec 2022 Ronapreve* SARS-CoV-2 hospitalized Filed Jan 2022 RG6264 Columvi (glofitamab) RG6026 3L+ DLBCL RG6107 Filed April 2022 RG1569 Actemra SS-ILD RG6026 Filed Aug 2022 Tecentriq SC Phesgo HER-2+ BC Filed July 2022 crovalimab PNH Filed Aug 2022 Columvi (glofitamab) 3L+ DLBCL Filed Dec 2022 RG1569 RG7446 all approved indications Filed Nov 2022 Status as of April 26, 2023 New Molecular Entity (NME) Additional Indication (Al) Oncology/Hematology Immunology Infectious Diseases Metabolism Neuroscience Ophthalmology Other SC=Subcutaneous *Ronapreve (casirivimab+imdevimab also known as REGEN-COV in the US) developed in collaboration with Regeneron Pharmaceuticals 57 57#58Major granted approvals 2023 US Polivy Xofluza EU RG7596 1L DLBCL (US) April 2023 RG6152 influenza pediatric RG7596 Jan 2023 Hemlibra RG6013 moderate hemophilia A Jan 2023 RG7596 Status as of April 26, 2023 New Molecular Entity (NME) Additional Indication (Al) Oncology/Hematology Immunology Infectious Diseases RG6152 Metabolism Neuroscience Ophthalmology Other China Polivy 1L DLBCL Jan 2023 Polivy r/r DLBCL Jan 2023 Xofluza influenza pediatric 5 to <12 years March 2023 Japan-Chugai Roche 58